Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q2 2023 · 10-Q
Revenue$0.00$0.00derived— vs Q2 2022 Net Income-$2.61M-$2.61MN/M vs Q2 2022 EPS Diluted-$1.94-$1.94N/M vs Q2 2022 Operating Income-$2,714,465N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,064,469N/M ended Jun 30, 2023 · filed Aug 10, 2023 · 41 d after period end